Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Keratosis, Actinic 6Carcinoma, Basal Cell 2Skin Diseases 1Precancerous Conditions 1Neoplasms, Basal Cell 1Keratosis 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Cyclosporine 4Antilymphocyte Serum 4Aminolevulinic Acid 4Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Etoposide 3Epoetin Alfa 3Darbepoetin alfa 3Busulfan 3Sirolimus 2Morphine 2Methylprednisolone 2Melphalan 2Filgrastim 2Biopsy 2tremelimumab 1tirbanibulin 1pyroxamide 1perillyl alcohol 1ferrous sulfate 1ferric gluconate 1arginine butyrate 1Triamcinolone 1Therapeutics 1Tetradecanoylphorbol Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precancerous Conditions × BF-200 ALA × Dermatologic × Clear all
NCT05060237 2024-10-17

Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Biofrontera Bioscience GmbH

Phase 1 Completed
112 enrolled 21 charts
DermatologicOther neoplasm

Keratosis, Precancerous Conditions, Skin Diseases, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡